(1993; 36 pages)
Special acknowledgement was made by the Committee to Dr S. Kopp-Kubel, Regulatory Support, and Miss M. Schmid, Quality Assurance, Division of Drug Management and Policies, WHO, Geneva, Switzerland, who were both instrumental in the preparation and proceedings of the meeting.
The Committee also acknowledged with thanks the valuable contributions made to its work by the following institutions and persons:
WHO Collaborating Centre for Drug Quality Control, Therapeutic Goods Administration Laboratories, Department of Community Services and Health, Woden, Australian Capital Territory, Australia; WHO Collaborative Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China; WHO Collaborating Centre for Biopharmaceutical Aspects of Drug Quality Control, Biopharmacy Laboratory, Faculty of Pharmacy, University of Clermont-Ferrand, Clermont-Ferrand, France; WHO Collaborating Centre for Stability Studies of Drugs, Regional and University Hospital Centre, Nantes, France; WHO Collaborating Centre for Drug Information and Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Government of India, Calcutta, India; WHO Collaborating Centre for Quality Assurance of Essential Drugs, The National Quality Control Laboratory of Drug and Food, Directorate General of Drug and Food Control, Ministry of Health, Jakarta, Indonesia; WHO Collaborating Centre for Chemical Reference Substances, The National Corporation of Swedish Pharmacies, Central Laboratory, Stockholm, Sweden; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Department of Medical Sciences, Ministry of Public Health, Bangkok, Thailand; WHO Collaborating Centre for Drug Quality Control, State Research Institute for the Standardization and Control of Drugs, Ministry of Health, Moscow, Russian Federation.
Professor J.-M. Aiache, Biopharmacy Laboratory, Faculty of Pharmacy, University of Clermont-Ferrand, France; Dr S. L. Ali, Association of German Pharmacists’ Central Laboratory, Eschborn, Germany; Dr H. Altdorfer, Pharmaceutical Institute, Swiss Federal Institute of Technology, Zurich, Switzerland; Professor E. Doelker, University of Geneva, Switzerland; Dr M.A. Kaukinen, Pharmaceutical Chemical Division, National Medicines Control Laboratory, Helsinki, Finland; Dr E. Keller, Ciba-Geigy, Basel, Switzerland; Dr S. Kliouev, Certification Department, Institute of Technology and Safety of Drugs, Moscow, Russian Federation; Dr T Layloff, Division of Drug Analysis, Food and Drug Administration, St Louis, MO, USA; Dr J. D. Nicholson, PSGB Medicines Testing Laboratory Edinburgh, Scotland; Professor L Ogunlana, Lanpharm Laboratory, Lagos, Nigeria; Dr S. Okada, Division of Drugs, National Institute of Hygienic Sciences, Osaka, Japan; Professor J. Richter, Berlin, Germany; Mr J. L. Turner, Medicines Control Agency, Department of Health, London, England; Dr W. Wieniawski, Polish Pharmacopoeia Commission, Warsaw, Poland.
Unfortunately the Committee was not in a position to name all those who contributed to the development of its report but wished to extend its thanks to them for their support.